glp-1 cardiovascular benefit The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Agonists in Cardiovascular Diseases:

Concurrently, they significantly delay gastric emptying and reduce caloric intake by enhancing satiety [61]

In addition to improved glycaemic control, GLP1R agonists demonstrate a direct effect on the reduction of both systemic and local inflammation, which is a plausible mechanism underpinning kidney protection

The pill is the second oral GLP-1 to reach the market in recent months, after Novo Nordisks Wegovy pill was approved in December

Acknowledgments This work was supported by the Core Facility of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine

Omada also expects 2026 adjusted EBITDA in the range of $7 million to $15 million, with the midpoint reflecting a $5 million increase compared to last year.